In a report published in the Journal of General Internal Medicine, researchers at Yale University looked at 97 drug ads that aired on television in 2015 and the first half of 2016. Most were targeted to people with arthritis, diabetes, and other ailments that require continuous care. None of them offered objective information about the potential risks of the drugs; the focus was instead on relative improvement in quality of life. In 13 percent of the ads, the drug companies suggested that various diabetes medications could be used off-label to reduce weight or lower blood pressure, a violation of FDA policy.
The spots also emphasized positive results of clinical trials. These efficacy statements dominated the narrative, with statements like “most people using [the drug] saw 75 percent clearer skin,” or “my doctor said [the drug] helps my bones get stronger.” The Yale study concluded that these and similar claims were potentially misleading and difficult to analyze objectively.